Amyloidosis Forum Scientific Workshop
January 22nd, 2021
Considerations for Novel Endpoint Development in AL Amyloidosis
Following the most recent Amyloidosis Forum held on October 15, 2020 (archived here), several different organ-specific working groups have formed through the ARC/FDA public private partnership to facilitate the development of a composite or multidomain endpoint for AL amyloidosis. The objective of each working group has been to identify and prioritize the most important organ-specific endpoints that could be considered as components to a composite or multidomain endpoint in AL amyloidosis. This Amyloidosis Forum meeting will bring together each of these organ-specific working groups along with independent and regulatory statisticians to discuss the output of each working group and potential components to a composite or multidomain endpoint in AL amyloidosis.